Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.KRRO · Entity 6388 | Chief Medical Officer | February 03, 2025 | February 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-02 | Direct | 42,000 |
Reported balance
After 2025-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-03 · Grant · Acquired 42,000 · Balance 42,000 F1: The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 5, 2025 16:14 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $33.50 | $0.00 |
DisclosureSEC source: 0000950170-25-014478 · ownership.xml · derivative · entry 1 Olugemo Olukemi · CIK 0002022212 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments commencing from February 3, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 19:12 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $50.48 | $0.00 |
DisclosureSEC source: 0000950170-24-068981 · ownership.xml · derivative · entry 1 Olugemo Olukemi · CIK 0002022212 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-02 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on May 13, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.